Mylan (NSDQ:MYL) said again today that it makes just $104 profit on its $600 EpiPen, after the Wall Street Journal reported that the company applied the statutory U.S. tax rate of 37.5% for its testimony before the Senate, according to Reuters.
“Without the tax-related reduction, Mylan’s profits on the EpiPen 2-pack would be closer to $160, or 60% higher than the figure the company gave Congress,” the WSJ report said.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan clarifies $104 profit on $600 EpiPens appeared first on MassDevice.
from MassDevice http://ift.tt/2cIiUcb
Cap comentari:
Publica un comentari a l'entrada